Cargando…

Na(+) Regulation in the Malaria Parasite Plasmodiumfalciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials

The malaria parasite Plasmodium falciparum establishes in the host erythrocyte plasma membrane new permeability pathways that mediate nutrient uptake into the infected cell. These pathways simultaneously allow Na(+) influx, causing [Na(+)] in the infected erythrocyte cytosol to increase to high leve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spillman, Natalie J., Allen, Richard J.W., McNamara, Case W., Yeung, Bryan K.S., Winzeler, Elizabeth A., Diagana, Thierry T., Kirk, Kiaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574224/ https://www.ncbi.nlm.nih.gov/pubmed/23414762 http://dx.doi.org/10.1016/j.chom.2012.12.006

Ejemplares similares

Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials
por: Flannery, Erika L., et al.
Publicado: (2014)

The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs
por: Spillman, Natalie Jane, et al.
Publicado: (2015)

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4
por: Ashton, Trent D., et al.
Publicado: (2023)

Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor
por: Goldgof, Gregory M., et al.
Publicado: (2016)

Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach
por: N., Nagasundaram, et al.
Publicado: (2016)

Mechanistic Study of the Spiroindolones: A New Class of Antimalarials
por: Zou, Bin, et al.
Publicado: (2012)

Status of potential PfATP6 molecular markers for artemisinin resistance in Suriname
por: Adhin, Malti R, et al.
Publicado: (2012)

Questions over high frequency of mutant PfATP6 haplotypes in traveller isolates
por: Woodrow, Charles J, et al.
Publicado: (2012)

A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4
por: Gilson, Paul R., et al.
Publicado: (2019)

A G358S mutation in the Plasmodium falciparum Na(+) pump PfATP4 confers clinically-relevant resistance to cipargamin
por: Qiu, Deyun, et al.
Publicado: (2022)

Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors
por: Tewari, Shivendra G., et al.
Publicado: (2023)

Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections
por: Pillai, Dylan R, et al.
Publicado: (2012)

Structure-based drug design studies of the interactions of ent-kaurane diterpenes derived from Wedelia paludosa with the Plasmodium falciparum sarco/endoplasmic reticulum Ca(2+)-ATPase PfATP6
por: Guimarães, Daniel Silqueira Martins, et al.
Publicado: (2015)

Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
por: Lakshminarayana, Suresh B., et al.
Publicado: (2015)

Purified E255L Mutant SERCA1a and Purified PfATP6 Are Sensitive to SERCA-type Inhibitors but Insensitive to Artemisinins
por: Cardi, Delphine, et al.
Publicado: (2010)

Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria
por: Yeung, Bryan K. S., et al.
Publicado: (2010)

PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion
por: Barnes, Claudia B. G., et al.
Publicado: (2022)

New Trifluoromethyl Triazolopyrimidines as Anti-Plasmodiumfalciparum Agents
por: Boechat, Núbia, et al.
Publicado: (2012)

SAM domain-dependent activity of PfTKL3, an essential tyrosine kinase-like kinase of the human malaria parasite Plasmodiumfalciparum
por: Abdi, Abdirahman, et al.
Publicado: (2010)

A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014)

Reply to “Misclassification of PfEH1 and PfEH2 as Epoxide Hydrolases”
por: Goldberg, Daniel E., et al.
Publicado: (2017)

Pfatp6 molecular profile of Plasmodium falciparum isolates in the western Brazilian Amazon
por: Brasil, Larissa W, et al.
Publicado: (2012)

Frequency and distribution of mixed Plasmodiumfalciparum-vivax infections in French Guiana between 2000 and 2008
por: Ginouves, Marine, et al.
Publicado: (2015)

Homology modeling, docking, and ADMET studies of benzoheterocyclic 4-aminoquinolines analogs as inhibitors of Plasmodiumfalciparum
por: Ibrahim, Zakari Y., et al.
Publicado: (2023)

A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
por: Leong, Joel, et al.
Publicado: (2014)

Spiroindolone Analogues as Potential Hypoglycemic with Dual Inhibitory Activity on α-Amylase and α-Glucosidase
por: Altowyan, Mezna Saleh, et al.
Publicado: (2019)

Discovery of Small-Molecule Allosteric Inhibitors of PfATC as Antimalarials
por: Wang, Chao, et al.
Publicado: (2022)

Genetic validation of PfFKBP35 as an antimalarial drug target
por: Thommen, Basil T, et al.
Publicado: (2023)

Prioritization of Molecular Targets for Antimalarial Drug Discovery
por: Forte, Barbara, et al.
Publicado: (2021)

A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609
por: Zhang, Rou, et al.
Publicado: (2016)

Antimalarial Peptide and Polyketide Natural Products from the Fijian Marine Cyanobacterium Moorea producens
por: Sweeney-Jones, Anne Marie, et al.
Publicado: (2020)

Plasmodiumfalciparum GFP-E-NTPDase expression at the intraerythrocytic stages and its inhibition blocks the development of the human malaria parasite
por: Borges-Pereira, Lucas, et al.
Publicado: (2017)

Probing the Open Global Health Chemical Diversity Library for Multistage-Active Starting Points for Next-Generation Antimalarials
por: Abraham, Matthew, et al.
Publicado: (2020)

The genomic architecture of antimalarial drug resistance
por: Cowell, Annie N, et al.
Publicado: (2019)

Characterization of PfTrxR inhibitors using antimalarial assays and in silico techniques
por: Munigunti, Ranjith, et al.
Publicado: (2013)

Orthosteric–allosteric dual inhibitors of PfHT1 as selective antimalarial agents
por: Huang, Jian, et al.
Publicado: (2021)

Drug resistance genomics of the antimalarial drug artemisinin
por: Winzeler, Elizabeth A, et al.
Publicado: (2014)

Polymorphism of PfATPase in Niger: detection of three new point mutations
por: Ibrahim, Maman Laminou, et al.
Publicado: (2009)

Identification and Functional Validation of the Novel Antimalarial Resistance Locus PF10_0355 in Plasmodium falciparum
por: Van Tyne, Daria, et al.
Publicado: (2011)

Spiroindolone analogues bearing benzofuran moiety as a selective cyclooxygenase COX-1 with TNF-α and IL-6 inhibitors
por: Altowyan, Mezna Saleh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c9lh1bgs34f94bltgd9ivb0smg